

Akronym	Bezeichnung	Phase	Indikation	Beschreibung	Rekrutierung
IPF STUDIEN					
ISABELA 1 &2	GLPG1690-CL-304	III	Idiopathische Lungenfibrose	A Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multi-center study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis.	Rekrutierung beendet
Juniper	ND-L02s-0201-005	II	Idiopathische Lungenfibrose	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects with Idiopathic Pulmonary Fibrosis (IPF)	Aktiv
VAY736 Novartis	CVAY736X2207	II	Idiopathische Lungenfibrose	A subject-, investigator-, and sponsor-blinded, randomized, placebo-controlled, multicenter study to investigate efficacy, safety, and tolerability of VAY736 in patients with idiopathic pulmonary fibrosis	Rekrutierung beendet
ZEPHYRUS	FibroGen FGCL-3019-091	III	Idiopathische Lungenfibrose	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF)	In Vorbereitung
Celgene	CC-90001-IPF-001	II	Idiopathische Lungenfibrose	A Phase 2, 24-Week, Randomized, Double-blind, Placebo-controlled, multicenter Study, with an 80 week active Treatment Extension, to evaluate the efficacy and safety of CC-90001 in Subjects with IPF.	Aktiv
BI 1305-0013	1305-0013	II	Idiopathische Lungenfibrose	A randomized, double-blind, placebo-controlled parallel group study in IPF patients over 12 weeks evaluating efficacy, safety and tolerability of BI 1015550 18 mg taken orally b.i.d.	Aktiv

Pliant	PLN-74809-IPF-202	IIa	Idiopathische Lungenfibrose	A randomized, double-blind dose-ranging, placebo-controlled Phase 2a evaluation of the safety, tolerability and pharmacokinetics of PLN-74809 in participants with idiopathic pulmonary fibrosis (IPF).	In Vorbereitung
BMS	IM027-040	II	Idiopathische Lungenfibrose	A Multicenter, randomized, double-blind, placebo-controlled, phase 2 study of the Efficacy and Safety and Tolerability of BMS-986278 in Participants with pulmonary Fibrosis.	Aktiv
Galactic	Galactic-1	IIb	Idiopathische Lungenfibrose	A randomized, double-blind, multicentre, parallel, placebo-controlled Phase 2b study in subjects with idiopathic pulmonary fibrosis (IPF) investigating the efficacy and safety of TD139, an inhaled galectin-3 inhibitor administered via a dry powder inhaler over 52 weeks.	Aktiv
Trevi	244098 TR 12	II	Idiopathische Lungenfibrose	A Phase 2, Double-blind, Randomized, Placebo-controlled, two treatment, two period crossover Efficacy and Safety Study in Idiopathic Pulmonary Fibrosis with Nalbupline ER Tablets for the treatment of Cough.	In Vorbereitung
Roche	WA-42293	III	Idiopathische Lungenfibrose	A Phase III Randomized, Double –Blind, placebo-controlled trial to evaluate the efficacy and Safety of PRM-151 in patients with idiopathic pulmonary fibrosis.	In Vorbereitung
Nicht-IPF STUDIEN					
INBUILD-ON	1199.248	III	PF-ILD	An open-label extension trial of the long term safety of nintedanib in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)	Rekrutierung beendet

Alveolar Proteinose STUDIEN

IMPALA	IMPALA MOL PAP 202 Extension	III	Alveolar Proteinose	An open-label,non-controlled, multicentre trial of inhaled Molgramotism in autoimmune pulmonary alveolar proteinosis patients	Rekrutierung beendet
IMPALA 2	IMPALA MOL PAP	III	Alveolar Proteinose	An open-label,non-controlled, multicentre trial of inhaled Molgramotism in autoimmune pulmonary alveolar proteinosis patients	In Vorbereitung

Sarkoidose STUDIEN

Novartis	CCMK389X2201	II	Sarkoidose	A subject and investigator blinded, randomized, placebocontrolled, repeat-dose, multicenter study to investigate efficacy, safety, and tolerability of CMK389 in patients with chronic pulmonary sarcoidosis.	Aktiv
-----------------	--------------	----	------------	--	--------------